[HTML][HTML] Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients
A Duminuco, S Scarso, A Cupri, NL Parrinello… - Journal of Clinical …, 2023 - mdpi.com
Ruxolitinib is a JAK1/2 inhibitor that has revolutionized the approach to myelofibrosis. On the
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients
A Duminuco, S Scarso, A Cupri… - JOURNAL OF …, 2023 - iris.uniroma1.it
Ruxolitinib is a JAK1/2 inhibitor that has revolutionized the approach to myelofibrosis. On the
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
[引用][C] Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients
A Duminuco, S Scarso, A Cupri, NL Parrinello, L Villari… - J. Clin. Med, 2023 - europepmc.org
Ruxolitinib is a JAK1/2 inhibitor that has revolutionized the approach to myelofibrosis. On the
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients
A Duminuco, S Scarso, A Cupri… - Journal of clinical …, 2023 - pubmed.ncbi.nlm.nih.gov
Ruxolitinib is a JAK1/2 inhibitor that has revolutionized the approach to myelofibrosis. On the
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients.
A Duminuco, S Scarso, A Cupri… - Journal of Clinical …, 2023 - search.ebscohost.com
Ruxolitinib is a JAK1/2 inhibitor that has revolutionized the approach to myelofibrosis. On the
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients
A Duminuco, S Scarso, A Cupri… - Journal of Clinical …, 2023 - search.proquest.com
Ruxolitinib is a JAK1/2 inhibitor that has revolutionized the approach to myelofibrosis. On the
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
[PDF][PDF] Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients
A Duminuco, S Scarso, A Cupri, NL Parrinello, L Villari… - J. Clin. Med, 2023 - iris.unict.it
Ruxolitinib is a JAK1/2 inhibitor that has revolutionized the approach to myelofibrosis. On the
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
[HTML][HTML] Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients
A Duminuco, S Scarso, A Cupri… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
Ruxolitinib is a JAK1/2 inhibitor that has revolutionized the approach to myelofibrosis. On the
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
[PDF][PDF] Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients
A Duminuco, S Scarso, A Cupri, NL Parrinello… - J. Clin …, 2023 - pdfs.semanticscholar.org
Ruxolitinib is a JAK1/2 inhibitor that has revolutionized the approach to myelofibrosis. On the
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
[PDF][PDF] Leishmania Infection during Ruxolitinib Treatment: The Cytokines-Based Immune Response in the Setting of Immunocompromised Patients
A Duminuco, S Scarso, A Cupri, NL Parrinello, L Villari… - J. Clin. Med, 2023 - iris.unict.it
Ruxolitinib is a JAK1/2 inhibitor that has revolutionized the approach to myelofibrosis. On the
one side, this drug can rapidly improve the symptoms related to the hematological disease; …
one side, this drug can rapidly improve the symptoms related to the hematological disease; …